{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:31:40Z","timestamp":1794947500214,"version":"4.9.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate high-frequency, high-intensity transcutaneous electrical nerve stimulation (TENS) as an inexpensive, noninvasive pain management approach for first-trimester aspiration abortion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a noninferiority, single-blind, randomized controlled trial of patients seeking aspiration abortion at up to 83 days of gestation. Participants received TENS (placed posteriorly, T10-L1 and S2-S4) or intravenous (IV) sedation (fentanyl, midazolam). The primary outcome was pain with aspiration, as self-reported by visual analog scale (VAS, 100 mm). To detect at least a 15 mm mean difference on the 100 mm VAS with 90% power and a significance level of .05, a total of 90 participants were required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Between January 2018 and October 2019, we enrolled 109 participants (55 TENS, 54 IV). Participant median gestation was 53 days (range 36\u201382) in the TENS group and 58 days (range 35\u201382) in the IV group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.65). Group demographics and clinical histories were similar. Intention-to-treat analysis (n=109) yielded noninferior results for the primary outcome (mean difference 4.8 mm, 95% CI \u22125.9 to 13.5 mm). In the per-protocol analysis, 9 (16%) in the TENS group were excluded after receiving IV sedation; 100 participants were included (46 TENS, 54 IV). Median (range) reported VAS for aspiration was 73 mm (13\u201397) and 66 mm (0\u201399) in the TENS and IV groups, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.40). With a mean difference of 4.4 mm (95% CI \u22125.6 to 14.5 mm), we found TENS to be noninferior to IV. Physicians underestimated participant pain, perceiving pain to be 34 mm (6\u201391) in the TENS group and 25 mm (0\u201383) in the IV group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>We found TENS to be a noninferior alternative to IV sedation for aspiration pain during first-trimester abortion. Expanding pain management options can improve quality of and access to abortion. Transcutaneous electrical nerve stimulation could be a standalone or adjunct approach for abortion pain management for those without access to or are ineligible to receive IV sedation due to the lack of sedation practitioner, designated driver, or local restrictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT03187002.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004502","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T18:00:21Z","timestamp":1628186421000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Transcutaneous Electrical Nerve Stimulation for Pain Management of Aspiration Abortion up to 83 Days of Gestation"],"prefix":"10.1097","volume":"138","author":[{"given":"Klaira","family":"Lerma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Goldthwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"R1-20261117","first-page":"1904","article-title":"Population group abortion rates and lifetime incidence of abortion: United States, 2008\u20132014","volume":"107","author":"Jones","year":"2017","journal-title":"Am J Public Health"},{"key":"R4-20261117","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/jmwh.12445","article-title":"Nonpharmaceutical pain control adjuncts during first-trimester aspiration abortion: a review","volume":"61","author":"Tschann","year":"2016","journal-title":"J Midwifery Women's Health"},{"key":"R5-20261117","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/AOG.0b013e3181938758","article-title":"Oral compared with intravenous sedation for first-trimester surgical abortion: a randomized controlled trial","volume":"113","author":"Allen","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R6-20261117","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/204946370700100103","article-title":"Transcutaneous electrical nerve stimulation: mechanisms, clinical application and evidence","volume":"1","author":"Johnson","year":"2007","journal-title":"Rev Pain"},{"key":"R7-20261117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/AOG.0000000000004208","article-title":"Transcutaneous electrical nerve stimulation to reduce pain with medication abortion: a randomized controlled trial","volume":"137","author":"Goldman","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R8-20261117","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pain.2009.10.023","article-title":"High-frequency, high-intensity transcutaneous electrical nerve stimulation as treatment of pain after surgical abortion","volume":"148","author":"Platon","year":"2010","journal-title":"Pain"},{"key":"R9-20261117","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/AOG.0000000000001842","article-title":"Transcutaneous nerve stimulation for pain relief during office hysteroscopy: a randomized controlled trial","volume":"129","author":"Lis\u00f3n","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R10-20261117","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.contraception.2009.12.008","article-title":"Pain control in first-trimester surgical abortion: a systematic review of randomized controlled trials","volume":"81","author":"Renner","year":"2010","journal-title":"Contraception"},{"key":"R11-20261117","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/AOG.0000000000001532","article-title":"Self-administered lidocaine gel for pain control with first-trimester surgical abortion: a randomized controlled trial","volume":"128","author":"Conti","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R12-20261117","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.contraception.2008.11.005","article-title":"First-trimester surgical abortion practices: a survey of National Abortion Federation members","volume":"79","author":"O'Connell","year":"2009","journal-title":"Contraception"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:00:25Z","timestamp":1794945625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004502"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004502","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740601521.793588440","asserted-by":"object"}]},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"2021-03-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}